Carol M. Stewart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carol M. Stewart has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Joseph Katz
4 shared publicationsRobert E. Bates
Department of Prosthodontics University of Florida College of Dentistry
4 shared publicationsGregory E. Smith
Department of Operative Dentistry University of Florida College of Dentistry
3 shared publications- Seunghee Cha
University of Florida
3 shared publications Indraneel Bhattacharyya
Univ Florida, Ctr Autoimmune Disorders, Dept Oral & Maxillofacial Surg & Diagnost Sci, Coll Dent, Gainesville, FL 32610 USA
2 shared publications- Indraneel Bhattacharyya
Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida , Gainesville, FL
2 shared publications
Latest Publications
- 2 September 2022
- Published by Springer Nature in Clinical Dentistry Reviewed
- Vol. 6 (1) , 1-14
Diagnosis of Sjögren’s disease
- 2 September 2022
- Published by Springer Nature in Clinical Dentistry Reviewed
- Vol. 6 (1) , 1-14
Diagnosis of Sjögren’s disease
- 30 May 2021
- Published by Springer Nature
- p. 3-20
Introduction, Diagnostic Criteria, Pharmacotherapy, and Dental Management
- 30 May 2021
- Published by Springer Nature
- p. 3-20
Introduction, Diagnostic Criteria, Pharmacotherapy, and Dental Management
- Open Access
- 3 May 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-13
Sjögren’s syndrome-associated microRNAs in CD14+ monocytes unveils targeted TGFβ signaling
Sjögren’s syndrome (SjS) monocytes have a pro-inflammatory phenotype, which may influence SjS pathogenesis. MicroRNAs (miRNAs) are small endogenously expressed molecules that can inhibit protein expression of their targeted genes and have important functions in regulating cell signaling responses. We profiled miRNAs in SjS monocytes to identify a SjS-specific miRNA profile and determine the potential roles of miRNAs in SjS pathogenesis. Total RNA was extracted from healthy control (HC, n = 10), SjS (n = 18), systemic lupus erythematosus (SLE, n = 10), and rheumatoid arthritis (RA, n = 10) peripheral blood CD14+ monocytes for miRNA microarray analysis. To validate select miRNAs from the microarray analysis, the original cohort and a new cohort of monocyte RNA samples from HC (n = 9), SjS (n = 12), SLE (n = 8), and RA (n = 9) patients were evaluated by quantitative reverse transcription (RT)-PCR. Functional predictions of differentially expressed miRNAs were determined through miRNA target prediction database analyses. Statistical analyses performed included one-way analysis of variance with Bonferroni post tests, linear regression, and receiver operating characteristic curve analyses. MiRNAs were predominantly upregulated in SjS monocytes in comparison with controls. Quantitative RT-PCR confirmations supported co-regulation of miR-34b-3p, miR-4701-5p, miR-609, miR-300, miR-3162-3p, and miR-877-3p in SjS monocytes (13/30, 43.3 %) in comparison with SLE (1/17, 5.8 %) and RA (1/18, 5.6 %). MiRNA-target pathway predictions identified SjS-associated miRNAs appear to preferentially target the canonical TGFβ signaling pathway as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFkB pathways. Our results underscore a novel underlying molecular mechanism where SjS-associated miRNAs may collectively suppress TGFβ signaling as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFκB pathways in SjS pathogenesis.
- 3 May 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-13
Open AccessSjögren’s syndrome-associated microRNAs in CD14+ monocytes unveils targeted TGFβ signaling
Sjögren’s syndrome (SjS) monocytes have a pro-inflammatory phenotype, which may influence SjS pathogenesis. MicroRNAs (miRNAs) are small endogenously expressed molecules that can inhibit protein expression of their targeted genes and have important functions in regulating cell signaling responses. We profiled miRNAs in SjS monocytes to identify a SjS-specific miRNA profile and determine the potential roles of miRNAs in SjS pathogenesis. Total RNA was extracted from healthy control (HC, n = 10), SjS (n = 18), systemic lupus erythematosus (SLE, n = 10), and rheumatoid arthritis (RA, n = 10) peripheral blood CD14+ monocytes for miRNA microarray analysis. To validate select miRNAs from the microarray analysis, the original cohort and a new cohort of monocyte RNA samples from HC (n = 9), SjS (n = 12), SLE (n = 8), and RA (n = 9) patients were evaluated by quantitative reverse transcription (RT)-PCR. Functional predictions of differentially expressed miRNAs were determined through miRNA target prediction database analyses. Statistical analyses performed included one-way analysis of variance with Bonferroni post tests, linear regression, and receiver operating characteristic curve analyses. MiRNAs were predominantly upregulated in SjS monocytes in comparison with controls. Quantitative RT-PCR confirmations supported co-regulation of miR-34b-3p, miR-4701-5p, miR-609, miR-300, miR-3162-3p, and miR-877-3p in SjS monocytes (13/30, 43.3 %) in comparison with SLE (1/17, 5.8 %) and RA (1/18, 5.6 %). MiRNA-target pathway predictions identified SjS-associated miRNAs appear to preferentially target the canonical TGFβ signaling pathway as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFkB pathways. Our results underscore a novel underlying molecular mechanism where SjS-associated miRNAs may collectively suppress TGFβ signaling as opposed to pro-inflammatory interleukin-12 and Toll-like receptor/NFκB pathways in SjS pathogenesis.
- 23 October 2015
- Published by Elsevier in Molecular Immunology
- Vol. 68 (2) , 606-616
Dysregulated co-stimulatory molecule expression in a Sjögren’s syndrome mouse model with potential implications by microRNA-146a
- 23 October 2015
- Published by Elsevier in Molecular Immunology
- Vol. 68 (2) , 606-616
Dysregulated co-stimulatory molecule expression in a Sjögren’s syndrome mouse model with potential implications by microRNA-146a
- 1 December 2009
- Published by Wiley in Journal of Dental Education
- Vol. 73 (12) , 1427
Dentist's Guide to Medical Conditions and Complications
- 1 December 2009
- Published by Wiley in Journal of Dental Education
- Vol. 73 (12) , 1427
Dentist's Guide to Medical Conditions and Complications
- 25 September 2008
- Vol. 56 (6) , 559-62
Florid cemento-osseous dysplasia mimicking multiple periapical pathology--an endodontic dilemma.
A case of florid cemento-osseous dysplasia (COD) mimicking periapical pathology is presented. The fact that the patient's lesion failed to resolve three years after root canal therapy, in addition to the presence of a mixed radiolucency with discreet radiopacities, mandated a biopsy which (along with radiographic co-relation) confirmed the diagnosis of cemento-osseous dysplasia. This case report illustrates the point that periapical radiolucencies may represent benign fibro-osseous lesions that may be overlooked or result in unnecessary endodontic treatment.
- 25 September 2008
- Vol. 56 (6) , 559-62
Florid cemento-osseous dysplasia mimicking multiple periapical pathology--an endodontic dilemma.
A case of florid cemento-osseous dysplasia (COD) mimicking periapical pathology is presented. The fact that the patient's lesion failed to resolve three years after root canal therapy, in addition to the presence of a mixed radiolucency with discreet radiopacities, mandated a biopsy which (along with radiographic co-relation) confirmed the diagnosis of cemento-osseous dysplasia. This case report illustrates the point that periapical radiolucencies may represent benign fibro-osseous lesions that may be overlooked or result in unnecessary endodontic treatment.
- 1 September 2008
- Published by Elsevier in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
- Vol. 106 (3) , 392-402
Labial salivary gland biopsies in Sjögren's syndrome: still the gold standard?
- 1 September 2008
- Published by Elsevier in Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology
- Vol. 106 (3) , 392-402
Labial salivary gland biopsies in Sjögren's syndrome: still the gold standard?
- 1 April 2008
- Vol. 39 (4) , 343-8
Xerostomia and lichenoid reaction in a hepatitis C patient treated with interferon-alpha: a case report.
Hepatitis C virus (HCV) infection is a liver disease characterized by the development of necrosis, inflammatory changes, and progressive liver fibrosis, leading to complications including cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The clinical features resemble those of other forms of acute viral hepatitis, namely, malaise, nausea, abdominal discomfort, pale stools, dark urine, and jaundice. The most frequently reported extrahepatic manifestations of HCV are lichen planus, sialadenitis, and cutaneous lesions. Sjogren's syndrome-like symptoms and lichenoid reactions have been previously reported in association with hepatitis C. This article describes a case of sicca-like syndrome and oral lichenoid reaction associated with interferon-alpha therapy for HCV infection. In this unique case, significant oral symptoms arose right after initiation of interferon-alpha treatment and resolved completely within days upon completion of treatment with interferon-alpha. Physicians and oral health care specialists should be aware of the association among HCV infection, interferon-alpha therapy, and development of possible oral signs and symptoms including lichenoid lesions and xerostomia.
- 1 April 2008
- Vol. 39 (4) , 343-8
Xerostomia and lichenoid reaction in a hepatitis C patient treated with interferon-alpha: a case report.
Hepatitis C virus (HCV) infection is a liver disease characterized by the development of necrosis, inflammatory changes, and progressive liver fibrosis, leading to complications including cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The clinical features resemble those of other forms of acute viral hepatitis, namely, malaise, nausea, abdominal discomfort, pale stools, dark urine, and jaundice. The most frequently reported extrahepatic manifestations of HCV are lichen planus, sialadenitis, and cutaneous lesions. Sjogren's syndrome-like symptoms and lichenoid reactions have been previously reported in association with hepatitis C. This article describes a case of sicca-like syndrome and oral lichenoid reaction associated with interferon-alpha therapy for HCV infection. In this unique case, significant oral symptoms arose right after initiation of interferon-alpha treatment and resolved completely within days upon completion of treatment with interferon-alpha. Physicians and oral health care specialists should be aware of the association among HCV infection, interferon-alpha therapy, and development of possible oral signs and symptoms including lichenoid lesions and xerostomia.
- 1 March 2008
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 139 (3) , 291-299
Salivary Dysfunction and Quality of Life in Sjögren Syndrome
- 1 March 2008
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 139 (3) , 291-299
Salivary Dysfunction and Quality of Life in Sjögren Syndrome
- 30 January 2008
- Published by Springer Nature in Rheumatology International
- Vol. 28 (8) , 771-776
Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren’s syndrome
The purpose of this study was to evaluate the levels of sRAGE in primary Sjögren’s syndrome (SS), and to assess whether there is an association between sRAGE levels and disease characteristics. Thirteen patients were randomly selected from three subgroups: primary SS, (n = 6), secondary Sjögren’s, (n = 4), and ANA(+) but lacking criteria for further disease classification (n = 3). Levels of serum sRAGE were measured in triplicate using an enzyme-linked immunosorbent assay kit. Mean sRAGE levels were significantly lower in the primary Sjögren’s group. Logistic regression analysis indicated that plasma sRAGE level was a significant predictor of diagnostic status. Analyses using routine serological tests for diagnosing autoimmune disorders failed to reach statistical significance. This preliminary study supports the hypothesis that the RAGE system might participate in the disease pathway of primary SS, and that sRAGE may be a potential biomarker to aid in the diagnosis of primary SS.
- 30 January 2008
- Published by Springer Nature in Rheumatology International
- Vol. 28 (8) , 771-776
Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren’s syndrome
The purpose of this study was to evaluate the levels of sRAGE in primary Sjögren’s syndrome (SS), and to assess whether there is an association between sRAGE levels and disease characteristics. Thirteen patients were randomly selected from three subgroups: primary SS, (n = 6), secondary Sjögren’s, (n = 4), and ANA(+) but lacking criteria for further disease classification (n = 3). Levels of serum sRAGE were measured in triplicate using an enzyme-linked immunosorbent assay kit. Mean sRAGE levels were significantly lower in the primary Sjögren’s group. Logistic regression analysis indicated that plasma sRAGE level was a significant predictor of diagnostic status. Analyses using routine serological tests for diagnosing autoimmune disorders failed to reach statistical significance. This preliminary study supports the hypothesis that the RAGE system might participate in the disease pathway of primary SS, and that sRAGE may be a potential biomarker to aid in the diagnosis of primary SS.